# Menin

Source: https://onco.cc/targets/menin/  
OnCo record `menin` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A scaffold protein that certain leukaemias need to keep their genes switched on; the first drug against it was approved in 2024.

## Summary

Menin (encoded by MEN1) is a scaffold protein that links KMT2A fusion proteins to chromatin; small-molecule inhibitors displace the complex, switch off the leukaemia gene programme and let blasts differentiate. Revumenib (Revuforj) is approved for KMT2A-rearranged and NPM1-mutant acute leukaemia, and ziftomenib followed. NPM1 mutation is found in roughly 25 to 30 percent of AML and KMT2A rearrangement in about 5 to 10 percent, while KMT2A rearrangement drives around 70 percent of infant ALL. Menin inhibitors are the first transcription-complex disruptors in routine haematology, and combinations with venetoclax and azacitidine are in phase 3. Differentiation syndrome, QT prolongation and acquired MEN1 mutations that restore binding are the recognised open problems. It is a scaffold certain leukaemias need to keep their genes on, and the first drug against it was approved in 2024.

## Fields

- Kind: Target
- Last checked: 2026-09-04
- Tags: epigenetic
- Symbol: MEN1
- Class: transcription
- Biology: Menin is a scaffold linking KMT2A fusion proteins to chromatin; inhibitors displace the complex and differentiate blasts.
- Where found: KMT2A-rearranged AML/ALL; NPM1-mutant AML

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Menin
- Wikipedia: https://en.wikipedia.org/wiki/Menin

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Acute myeloid leukaemia in children](https://onco.cc/cancers/aml-paediatric/), [Grade 3 well-differentiated neuroendocrine tumour](https://onco.cc/cancers/grade-3-net/), [Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year)](https://onco.cc/cancers/all-infant/), [Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4)](https://onco.cc/cancers/multiple-endocrine-neoplasia/), [Multiple endocrine neoplasia type 1 (MEN1)](https://onco.cc/cancers/men1-syndrome/), [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/), [NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia](https://onco.cc/cancers/aml-npm1-kmt2a/), [Pancreatic neuroendocrine tumours](https://onco.cc/cancers/pancreatic-net/)
- drugs: [Revumenib](https://onco.cc/drugs/revumenib/), [Ziftomenib](https://onco.cc/drugs/ziftomenib/)
- pathways: [Cancer stem cells & phenotypic plasticity](https://onco.cc/pathways/cancer-stem-cells-plasticity/), [Epigenetic reprogramming](https://onco.cc/pathways/epigenetic-reprogramming/), [Intrinsic apoptosis (BCL-2 family)](https://onco.cc/pathways/apoptosis-bcl2/), [Menin / KMT2A (HOXA9-MEIS1 axis)](https://onco.cc/pathways/menin-kmt2a/), [Transcriptional machinery & addiction](https://onco.cc/pathways/transcription-addiction/)
- terms: [Cancer stem cell theory and phenotypic plasticity](https://onco.cc/terms/cancer-stem-cell-theory/), [Differentiation syndrome](https://onco.cc/terms/differentiation-syndrome/), [Epigenetic progenitor theory: cancer without a first mutation](https://onco.cc/terms/epigenetic-progenitor-theory/), [Hallmark (2022): unlocking phenotypic plasticity](https://onco.cc/terms/unlocking-phenotypic-plasticity/), [MEN1 and hereditary neuroendocrine syndromes](https://onco.cc/terms/men1-hereditary-net/)
- targets: [HOXA9](https://onco.cc/targets/hoxa9/), [KMT2A (MLL) rearrangement](https://onco.cc/targets/kmt2a/), [MEIS1](https://onco.cc/targets/meis1/), [NPM1 mutation](https://onco.cc/targets/npm1/)
- trials: [AUGMENT-101](https://onco.cc/trials/augment-101/), [KOMET-001](https://onco.cc/trials/komet-001/)
- pairings: [Menin inhibitor + venetoclax + azacitidine](https://onco.cc/pairings/menin-plus-venetoclax-hma/)
- ideas: [An open-science consortium on the undruggable drivers, open until a candidate](https://onco.cc/ideas/idea-fund-precompetitive-undruggable-consortium/), [Menin inhibitors for infant KMT2A-rearranged ALL](https://onco.cc/ideas/idea-menin-infant-all/)
- technologies: [Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)](https://onco.cc/technologies/epigenetic-drugs/), [Menin inhibitors](https://onco.cc/technologies/menin-inhibitors/)
- people: [Eunice S. Wang](https://onco.cc/people/eunice-wang/), [Eytan M. Stein](https://onco.cc/people/eytan-stein/), [Ghayas C. Issa](https://onco.cc/people/ghayas-issa/)
- bottlenecks: [The undruggable drivers](https://onco.cc/bottlenecks/b-undruggable-targets/)
- key papers: [AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation](https://onco.cc/key-papers/paper-augment-101-revumenib-menin-nature-2023/)
- roadmaps: [Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome](https://onco.cc/roadmaps/epigenetics-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/menin.json